Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

You can now review and comment on this draft guideline.

The consultation closes on 5pm, 02 December 2021

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline– just the recommendations

• Evidence reviews
  • Evidence review A - Patient information
  • Evidence review B - Prescribing strategies
  • Evidence review C - Safe withdrawal
  • Evidence review D - Withdrawal symptoms
  • Evidence review E - Risk Factors for Dependence or Withdrawal
  • Evidence review F - Monitoring Content and Frequency
• Methodology chapter

• Acknowledgements

• Benzodiazepine Economic Analysis Report

•  Other information about the consultation
  • Equality impact assessment
  • Committee member list
  • Developing NICE guidelines: how to get involved

3. Add your comments

• You must use this comments form.
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: safeprescribing@nice.org.uk

Deadline: 5pm, 02 December 2021